SANT-7

an IL-6 receptor antagonist

Also Known As:

SANT7

Networked: 7 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Intercellular Signaling Peptides and Proteins: 29768
    - Cytokines: 164289
      - Interleukins: 25257
        Interleukin-6: 55160
        SANT-7: 7
- Peptides: 82426
  - Intercellular Signaling Peptides and Proteins: 29768
    - Cytokines: 164289
      - Interleukins: 25257
        Interleukin-6: 55160
        SANT-7: 7
Biological Factors: 2472
- Intercellular Signaling Peptides and Proteins: 29768
  - Cytokines: 164289
    - Interleukins: 25257
      - Interleukin-6: 55160
        SANT-7: 7

Experts

1.	Carminati, Paolo: 2 articles (09/2005 - 08/2005)
2.	De Santis, Rita: 2 articles (09/2005 - 08/2005)
3.	Serlupi-Crescenzi, Ottaviano: 2 articles (09/2005 - 08/2005)
4.	Tagliaferri, Pierosandro: 2 articles (06/2005 - 10/2002)
5.	Tassone, Pierfrancesco: 2 articles (06/2005 - 10/2002)
6.	Venuta, Salvatore: 2 articles (06/2005 - 10/2002)
7.	Arseni, Brunilde: 1 article (09/2005)
8.	Campo, Silvia: 1 article (09/2005)
9.	Cherubini, G: 1 article (09/2005)
10.	Rossi, Stefania: 1 article (09/2005)

Related Diseases

1.	Neoplasms (Cancer) 09/07/2005 - "However, only marginal anti-tumor efficacy of the adenoviral Sant7 was observed. " 01/01/1999 - "The influence of IL-6 is controlled by treating PC-3 tumor cells with anti-IL-6 neutralizing antibody and, more efficiently, by a mutated IL-6, Sant7. "
2.	Multiple Myeloma 05/01/1997 - "On the basis of these results we propose the super-antagonist Sant7 as a possible candidate for the immunotherapy of multiple myeloma." 06/01/2005 - "Gene expression profiling of INA-6 cells showed down-regulation of proliferation/maintenance and cell cycle control genes, as well as up-regulation of apoptotic genes in multiple myeloma cells triggered by Sant7 and dexamethasone combination. " 09/01/2001 - "The IL-6 receptor antagonist SANT-7 overcomes bone marrow stromal cell-mediated drug resistance of multiple myeloma cells." 06/01/2005 - "Taken together, these results indicate that inhibition of IL-6 signaling by Sant7 significantly potentiates the therapeutic action of dexamethasone against multiple myeloma cells, providing the preclinical rationale for clinical trials of Sant7 in combination with dexamethasone to improve patient outcome in multiple myeloma." 06/01/2005 - "Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma."
3.	B-Cell Lymphoma (Lymphoma, B Cell) 09/07/2005 - "Comparative activity of Sant7 and anti-IL-6, IL-6R monoclonal antibodies in a murine model of B-cell lymphoma." 09/07/2005 - "This work describes the effects of the recombinant or adenovirally-delivered IL-6 superantagonist Sant7, anti-IL-6 and IL-6 receptor monoclonal antibodies in a severe murine model of human B-cell lymphoma induced in SCID mice by transplantation of an LCL-41 cell line variant (isotype-switched IgM>IgG). "
4.	Lymphoproliferative Disorders (Lymphoproliferative Disorder) 08/21/2005 - "We thus wanted to investigate the effect of the IL-6 receptor antagonist Sant7 on proliferative and anti-apoptotic signals in the IL-6-secreting LCL41 B lymphoid cells, taken from a patient with EBV-induced lymphoproliferative disorder. "

Related Drugs and Biologics

1.	Interleukin-6 (Interleukin 6)
2.	Dexamethasone (Maxidex)
3.	Interleukin-6 Receptors (Interleukin 6 Receptor)
4.	Neutralizing Antibodies
5.	Immunoglobulin M (IgM)
6.	Immunoglobulin G (IgG)
7.	Monoclonal Antibodies
8.	Zoledronic Acid (Zometa)

Related Therapies and Procedures

1.	Transplantation
2.	Therapeutics
3.	Immunotherapy